Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF XTEN
43.49 USD -0.04 (-0.09%)
Nov 11, 2026, 3:59 PM EST
43.34 Day range 43.49
41.84 52-week range 47.49
- YTD
- -5.92%
- 1 year
- -7.18%
News
defenseworld.net BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Stake Reduced by DUTCH ASSET Corp DUTCH ASSET Corp cut its stake in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 20.6% during the undefined quarter, according to its most recent Form 13F filing with…
defenseworld.net BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) Stock Short Interest Report for September BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short…
defenseworld.net 15,395 Shares in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Bought by Sax Wealth Advisors LLC Sax Wealth Advisors LLC bought a new position in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) during the undefined quarter, according to its most recent filing with…
businesswire.com Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked…
businesswire.com Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted…
etftrends.com Why Investors Are Eyeing Short & Long U.S. Treasury ETFs Considering where bond yields sit, along with geopolitical pressures and potential policy from the Fed, there are plenty of ways for advisors and investors to play the fixed income market at the…
businesswire.com Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500,…
defenseworld.net Park Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Park Avenue Securities LLC lowered its position in shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 19.8% during the undefined quarter, according to its most…
businesswire.com Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen…
defenseworld.net Heck Capital Advisors LLC Has $9.10 Million Stock Holdings in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Heck Capital Advisors LLC lifted its stake in shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 9.5% in the third quarter, according to its most recent Form…
businesswire.com Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company's Phase 1 clinical trial evaluating VIR-5500 in…
businesswire.com Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating VIR-5525, an…
etftrends.com BondBloxx Fixed Income ETFs Surpass $4 Billion in Total AUM Fixed income firm BondBloxx celebrated a new milestone recently, crossing $4 billion in ETF AUM. The firm offers more than 20 fixed income ETFs for investors, led by its largest fund, the BondBloxx…
etftrends.com Market Valuation, Inflation and Treasury Yields – January 2025 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
etftrends.com Market Valuation, Inflation and Treasury Yields – December 2024 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
etftrends.com Market Valuation, Inflation and Treasury Yields – November 2024 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
businesswire.com Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers…
etftrends.com Market Valuation, Inflation and Treasury Yields – October 2024 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
etftrends.com Market Valuation, Inflation and Treasury Yields – September 2024 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
etftrends.com Market Valuation, Inflation and Treasury Yields – August 2024 Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
benzinga.com 5 ETFs To Watch As 10-Year Treasury Approaches 5% Yield, Analysts Say It's Now A 'Buy' The 10-year Treasury bond is closely monitored by several exchange-traded funds (ETFs), including iShares 7-10 Year Treasury Bond ETF.
benzinga.com Economists See Recession Risk Waning, End Of Fed Rate Hikes: How Could Treasury ETFs React To Yields? Economists anticipate the 10-year Treasury yield to conclude this year at 4.47%, with a further drop to 4.16% by the end of June next year.